In last trading session, Protara Therapeutics Inc (NASDAQ:TARA) saw 0.53 million shares changing hands with its beta currently measuring 1.61. Company’s recent per share price level of $4.92 trading at $0.42 or 9.33% at ring of the bell on the day assigns it a market valuation of $168.85M. That closing price of TARA’s stock is at a discount of -113.01% from its 52-week high price of $10.48 and is indicating a premium of 67.48% from its 52-week low price of $1.60. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.26 million shares which gives us an average trading volume of 2.40 million if we extend that period to 3-months.
For Protara Therapeutics Inc (TARA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.56 in the current quarter.
Protara Therapeutics Inc (NASDAQ:TARA) trade information
Upright in the green during last session for gaining 9.33%, in the last five days TARA remained trading in the green while hitting it’s week-highest on Friday, 01/31/25 when the stock touched $4.92 price level, adding 1.4% to its value on the day. Protara Therapeutics Inc’s shares saw a change of -6.82% in year-to-date performance and have moved 8.61% in past 5-day. Protara Therapeutics Inc (NASDAQ:TARA) showed a performance of -6.82% in past 30-days. Number of shares sold short was 2.74 million shares which calculate 14.46 days to cover the short interests.
Protara Therapeutics Inc (TARA) estimates and forecasts
Statistics highlight that Protara Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 120.63% of value to its shares in past 6 months, showing an annual growth rate of 7.00% while that of industry is 17.20. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 39.98% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 7.10% while estimates for its earnings growth in next 5 years are of 15.23%.
Protara Therapeutics Inc (NASDAQ:TARA)’s Major holders
Insiders are in possession of 6.13% of company’s total shares while institution are holding 51.11 percent of that, with stock having share float percentage of 54.45%. Investors also watch the number of corporate investors in a company very closely, which is 51.11% institutions for Protara Therapeutics Inc that are currently holding shares of the company. OPALEYE MANAGEMENT INC. is the top institutional holder at TARA for having 2.3 million shares of worth $5.3 million. And as of 2024-06-30, it was holding 20.1758 of the company’s outstanding shares.
The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 1.9 million shares on 2024-06-30. The number of shares represents firm’s hold over 16.6361 of outstanding shares, having a total worth of $3.95 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 616.3 shares of worth $3.03 million or 2.99% of the total outstanding shares. The later fund manager was in possession of 140.67 shares on Sep 30, 2024 , making its stake of worth around $0.69 million in the company or a holder of 0.68% of company’s stock.
